Company BriaCell Therapeutics Corp.

Stocks

BCT

CA1079303071

Biotechnology & Medical Research

Market Closed - Toronto S.E. 15:59:52 2026-08-18 EDT			5-day change	1st Jan Change
4.850 ^CAD	+3.19%		+2.75%	-50.51%

08-05	BriaCell Gets FDA Approval to Start Phase 1/2a of Prostate Cancer Immunotherapy Study	MT
08-05	Briacell Therapeutics Corp Receives Fda Clearance to Initiate Bria-Pros+ Clinical Study in Prostate Cancer	CI

Business description: BriaCell Therapeutics Corp.

BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. Bria-IMT, its Phase 3 lead candidate, is a patented, off-the-shelf, cell-based, targeted immunotherapy that activates the patientâ€™s immune system to specifically kill cancer cells without harming other cells. The Company is advancing its Bria-IMT targeted immunotherapy in combination with an immune check point inhibitor (Retifanlimab) in a pivotal Phase 3 study in metastatic breast cancer. It is also developing personalized off-the-shelf immunotherapies, Bria-OTS and Bria-OTS+, which provides a platform technology to develop personalized off-the-shelf immunotherapies for numerous types of cancer, and a soluble CD80 protein therapeutic which act both as a stimulator of the immune system, as well as an immune checkpoint inhibitor. Its pipeline also includes Bria-IMT + CPI, Bria-BRES/BRES+, Bria-PROS+, Bria-LUNG+ and Bria-MEL+.

Number of employees: 16

Sales by Activity: BriaCell Therapeutics Corp.

Fiscal Period: July	2021 (USD)	2022 (USD)	2023 (USD)	2024 (USD)	2025 (USD)

See all business segments

Geographical breakdown of sales: BriaCell Therapeutics Corp.

Fiscal Period: July	2021 (USD)	2022 (USD)	2023 (USD)	2024 (USD)	2025 (USD)

See all geographic segments

Executive Committee: BriaCell Therapeutics Corp.

Manager	Title	Age	Since
William Williams CEO	Chief Executive Officer	70	2016-10-31
Gadi Levin DFI	Director of Finance/CFO	54	2016-01-31
Guiseppe Del Priore CTO	Chief Tech/Sci/R&D Officer	65	2022-02-15
Miguel Lopez-Lago CTO	Chief Tech/Sci/R&D Officer	56	2021-04-30

See BRIACELL THERAPEUTICS CORP. governance

Composition of the Board of Directors: BriaCell Therapeutics Corp.

Director	Title	Age	Since
William Williams BRD	Director/Board Member	70	2016-10-31
Jamieson Bondarenko CHM	Chairman	41	2019-04-23
Rebecca Taub BRD	Director/Board Member	74	2019-03-06
Vaughn Embro-Pantalony BRD	Director/Board Member	68	2019-03-17
Martin Schmieg BRD	Director/Board Member	63	2016-05-09
Jane Gross BRD	Director/Board Member	69	2022-01-17

Composition of the Board of Directors

Shareholders: BriaCell Therapeutics Corp.

Name	Stocks	%	Valuation
Citadel Advisors LLC 8.238 %	716,699	8.238 %	2 M $
Cable Car Capital LP 2.492 %	216,821	2.492 %	745 864 $
William Williams 1.379 %	119,992	1.379 %	412 772 $
Sabby Management LLC 0.9279 %	80,721	0.9279 %	277 680 $
Guiseppe Del Priore 0.8662 %	75,356	0.8662 %	259 225 $

Name	Stocks	%	Valuation
Citadel Advisors LLC (13f Subfiler) -	895,864	-	824 195 $
Armistice Capital LLC -	536,600	-	493 672 $
Cable Car Capital LP -	321,898	-	296 146 $
Empery Asset Management LP -	300,000	-	276 000 $
MYDA Advisors LLC -	195,821	-	180 155 $

Name	Stocks	%	Valuation
Heights Capital Management, Inc. -	313,379	-	28 204 $
Sabby Management LLC -	120,802	-	10 872 $
G1 Execution Services LLC -	114,522	-	10 307 $
HRT Financial LP -	67,935	-	6 114 $
Two Sigma Securities LLC -	15,060	-	1 355 $

List of BRIACELL THERAPEUTICS CORP. shareholders

Company details: BriaCell Therapeutics Corp.

BriaCell Therapeutics Corp.

Bellevue Centre

V7T 2X1, West Vancouver

+604 921 1810

http://www.briacell.com

address BriaCell Therapeutics Corp.(BCT)

Bio Therapeutic Drugs

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
BRIACELL THERAPEUTICS CORP.	+3.19%	+2.75%	-53.81%	-99.67%	29.48M
WUXI APPTEC CO., LTD.	+0.17%	+3.62%	+70.94%	+109.68%	73.25B
ARGENX SE	+1.73%	+13.43%	+57.10%	+90.54%	61.95B
INSMED INCORPORATED	+0.11%	-4.67%	+0.52%	+484.71%	28.02B
WUXI BIOLOGICS (CAYMAN) INC.	+5.24%	+5.33%	+57.01%	+17.77%	24.15B
BIONTECH SE	+1.26%	-0.05%	-18.30%	-18.08%	23.01B
PHARMAESSENTIA CORPORATION	-0.71%	+5.26%	+241.94%	+427.03%	18.35B
GENMAB A/S	0.00%	+5.62%	+40.50%	-15.26%	19.46B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+3.83%	+2.65%	+25.00%	+592.85%	15.92B
EXELIXIS, INC.	+1.53%	+0.30%	+38.66%	+152.95%	12.96B
Average	+1.64%	+1.07%	+45.96%	+174.25%	27.71B
Weighted average by Cap.	+1.25%	+3.43%	+57.12%	+166.70%